Dr Andrew Claridge

Dr Claridge has been a gastroenterologist at the Great Western Hospital in Swindon since 2014 and was clinical lead for gastroenterology from 2015 to 2022.  He is currently Training Program Director for Gastroenterology for the Severn Deanery, Specialty Research Lead for West of England at the NIHR / CRN, board member of the MRCP exam at the Royal College of Physicians and member of the European Specialty Examination in Gastroenterology and Hepatology (ESEGH) Examining Board.

He graduated from Manchester in 1999 and undertook training in New Zealand and Australia. He travelled widely as a junior doctor, completing a post graduate degree in expedition medicine with an interest in travelling with chronic diseases of the gastrointestinal tract. After settling into specialist training in Wessex he focused on illnesses of the lower gastrointestinal tract and completed a PhD in the role of microRNAs (a type of DNA) in inflammatory Bowel Disease.  He is a keen teacher and has a MSc in education.  He believes passionately in self-improvement and encourages patients to understand and manage their own illnesses.

He practices in all areas of gastroenterology, specifically symptoms relating to the gastrointestinal tract such as disorders of bowel habit, malabsorption and digestion, anaemia and abdominal discomfort.

Awards received

• MSD IBD Academy fellowship 2011/2012
• ECCO award 2011
• North West Kidney Club prize 1999

Research/publications

Ph.D. “A study of the role of microRNAs in Inflammatory Bowel Disease: The effect of miR-31 dysregulation in the expression of TSLP in Ulcerative Colitis”

• (2018). “MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1”
• (2017) “Sjogrens syndrome and the GUT”
• (2012) “Improving outpatient services: The Southampton IBD virtual clinic”
• (2012) “Treatment naïve Ulcerative Colitis has a distinctive microRNA profile”
• (2012) “The role of miRNAs mir-31 and mir-155 in the deregulation of the IL-13 pathway in Ulcerative Colitis”
• (2012) “Investigation of the action of histone deacetylase inhibitors in ex-vivo and in-vitro models of Inflammatory Bowel Disease”
• (2012) “MicroRNA expression in treatment naïve active and inactive Ulcerative Colitis”
• (2012) “The role of miRNAs mir-31 and mir-155 in the deregulation of the IL-13 pathway in Ulcerative Colitis”
• (2012) “The role of histone deacetylase inhibition in ex-vivo and in-vitro models of inflammatory bowel disease”
• (2011) “What is the educational value of ward rounds? A learner and teacher perspective”
• (2010) “Teaching and learning on busy post-take ward rounds”
• (2010) “Exotic travelling with IBD”
• (2009) “Gastrointestinal Emergencies”
• (2009) “IBD and Travelling: What is happing to our patients?”
• (2009) “Can nutritional state on admission be used to predict 30 day mortality in patients presenting with alcoholic liver disease?”
• (2006) “The Octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegally”
• (2005) “Do benign looking gastric ulcers need follow up endoscopy and biopsy?”
• (2002) “Screening for cystic fibrosis related diabetes”
• (2002) “A re-audit of screening for cystic fibrosis related diabetes”.